CD8A and infection: The recent success of RNA vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein to prevent COVID-19 disease [79], which elicit neutralizing titers comparable to natural infection and cellular immune responses with specific CD8+ and CD4+ T cell expansion [80,81], has raised interest in using this technology in vaccines against additional targets.